Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATIP NASDAQ:AVIR NYSE:FAII NASDAQ:NGNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATIPATI Physical Therapy$0.68$0.77$0.01▼$6.59$2.98M-0.159,934 shs10 shsAVIRAtea Pharmaceuticals$3.36-3.2%$3.56$2.45▼$4.14$266.64M0.25346,397 shs161,155 shsFAIIFortress Value Acquisition Corp. II$9.36$9.01▼$13.05$72.45MN/A845,837 shs376,711 shsNGNENeurogene$18.48-1.9%$20.38$6.88▼$74.49$263.75M1.69111,648 shs94,969 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATIPATI Physical Therapy0.00%0.00%0.00%-24.58%-88.42%AVIRAtea Pharmaceuticals0.00%-8.20%-7.69%+12.75%-11.58%FAIIFortress Value Acquisition Corp. II0.00%0.00%0.00%0.00%-72.28%NGNENeurogene0.00%-7.55%-15.11%+7.38%-48.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATIPATI Physical TherapyN/AN/AN/AN/AN/AN/AN/AN/AAVIRAtea Pharmaceuticals2.4141 of 5 stars3.30.00.00.03.32.51.3FAIIFortress Value Acquisition Corp. IIN/AN/AN/AN/AN/AN/AN/AN/ANGNENeurogene1.9818 of 5 stars3.40.00.00.02.31.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATIPATI Physical Therapy 0.00N/AN/AN/AAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0078.57% UpsideFAIIFortress Value Acquisition Corp. II 0.00N/AN/AN/ANGNENeurogene 2.75Moderate Buy$46.17149.82% UpsideCurrent Analyst Ratings BreakdownLatest FAII, ATIP, NGNE, and AVIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025NGNENeurogeneCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.006/12/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.00 ➝ $26.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATIPATI Physical Therapy$741.86M0.00$3.55 per share0.19($23.96) per share-0.03AVIRAtea PharmaceuticalsN/AN/AN/AN/A$4.59 per shareN/AFAIIFortress Value Acquisition Corp. IIN/AN/AN/AN/A$0.12 per shareN/ANGNENeurogene$930K283.56N/AN/A$19.15 per share0.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATIPATI Physical Therapy-$69.79M-$19.42N/A∞N/A-7.79%N/A-3.87%11/3/2025 (Estimated)AVIRAtea Pharmaceuticals-$168.38M-$1.61N/AN/AN/AN/A-32.55%-30.47%11/6/2025 (Estimated)FAIIFortress Value Acquisition Corp. II-$13.61MN/A0.00N/AN/AN/AN/AN/AN/ANGNENeurogene-$75.14M-$4.31N/AN/AN/AN/A-33.33%-30.34%11/17/2025 (Estimated)Latest FAII, ATIP, NGNE, and AVIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025NGNENeurogene-$1.15-$1.05+$0.10-$1.05N/AN/A8/7/2025Q2 2025AVIRAtea Pharmaceuticals-$0.46-$0.44+$0.02-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATIPATI Physical TherapyN/AN/AN/AN/AN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/AFAIIFortress Value Acquisition Corp. IIN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATIPATI Physical TherapyN/A1.121.12AVIRAtea PharmaceuticalsN/A19.1719.17FAIIFortress Value Acquisition Corp. IIN/A0.090.09NGNENeurogeneN/A18.0718.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATIPATI Physical Therapy72.60%AVIRAtea Pharmaceuticals86.67%FAIIFortress Value Acquisition Corp. II64.25%NGNENeurogene52.37%Insider OwnershipCompanyInsider OwnershipATIPATI Physical Therapy3.30%AVIRAtea Pharmaceuticals18.10%FAIIFortress Value Acquisition Corp. IIN/ANGNENeurogene11.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATIPATI Physical Therapy5,6004.41 million4.27 millionNo DataAVIRAtea Pharmaceuticals7079.36 million64.99 millionOptionableFAIIFortress Value Acquisition Corp. IIN/A43.13 millionN/ANot OptionableNGNENeurogene9014.27 million12.61 millionOptionableFAII, ATIP, NGNE, and AVIR HeadlinesRecent News About These CompaniesEntryPoint Capital LLC Purchases New Position in Neurogene Inc. $NGNEAugust 27, 2025 | marketbeat.comAnalysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $46.17August 27, 2025 | americanbankingnews.comNeurogene Inc. (NASDAQ:NGNE) Given Average Rating of "Moderate Buy" by BrokeragesAugust 24, 2025 | marketbeat.comWilliam Blair Issues Negative Outlook for Neurogene EarningsAugust 16, 2025 | marketbeat.comHC Wainwright Has Bearish Estimate for Neurogene Q3 EarningsAugust 16, 2025 | marketbeat.comQ3 Earnings Estimate for Neurogene Issued By Leerink PartnrsAugust 16, 2025 | marketbeat.comNeurogene Advances NGN-401 Gene Therapy for Rett SyndromeAugust 14, 2025 | theglobeandmail.comNeurogene (NASDAQ:NGNE) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPSAugust 12, 2025 | marketbeat.comNeurogene Inc. Reports Increased Losses Amid R&D FocusAugust 11, 2025 | tipranks.comNeurogene Reports Second Quarter 2025 Financial Results and Highlights Recent UpdatesAugust 11, 2025 | businesswire.comBlair William & Co. IL Increases Stock Position in Neurogene Inc. (NASDAQ:NGNE)August 10, 2025 | marketbeat.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2025 | businesswire.comRaiffeisen Bank International AG Has $351,000 Stake in Neurogene Inc. (NASDAQ:NGNE)August 7, 2025 | marketbeat.comNeurogene (NGNE) to Release Earnings on FridayAugust 1, 2025 | marketbeat.comBullish Neurogene Insiders Loaded Up On US$1.46m Of StockJuly 30, 2025 | finance.yahoo.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 5, 2025 | morningstar.comMNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business WireJuly 5, 2025 | businesswire.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | businesswire.comNeurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - MorningstarJuly 2, 2025 | morningstar.comMNeurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Business WireJuly 2, 2025 | businesswire.comStifel maintient sa recommandation d’achat sur l’action NeurogeneJuly 2, 2025 | fr.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFAII, ATIP, NGNE, and AVIR Company DescriptionsATI Physical Therapy NYSE:ATIP$0.68 0.00 (0.00%) As of 07/31/2025ATI Physical Therapy, Inc. operates as an outpatient physical therapy provider that specializes in outpatient rehabilitation and adjacent healthcare services in the United States. It offers a range of services to its patients, including physical therapy to treat spine, shoulder, knee, and neck injuries or pain; work injury rehabilitation services, work conditioning and work hardening; and hand therapy, aquatic therapy, functional capacity evaluation, sports medicine, and wellness programs. It also provides ATI worksite solutions comprising injury prevention programs, work-related injury assessment services, wellness offerings, and consultations for employers; proprietary electronic medical records (EMR) integration, caseload management, and continuing education in therapy treatments; and sports medicine, including on-site sports physical therapy, clinical evaluation and diagnosis, immediate and emergency care, nutrition programs, and concussion management services. The company offers outpatient physical therapy services under the ATI brand name. ATI Physical Therapy, Inc. was founded in 1996 and is based in Bolingbrook, Illinois.Atea Pharmaceuticals NASDAQ:AVIR$3.36 -0.11 (-3.17%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.36 +0.01 (+0.15%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Fortress Value Acquisition Corp. II NYSE:FAIIFortress Value Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.Neurogene NASDAQ:NGNE$18.48 -0.36 (-1.91%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$18.47 -0.01 (-0.05%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
